Showing results (131-140 of 232) with videos related to

Sort By:
Pageof 24
The American Journal of Clinical Nutrition|December 28, 2019
Race affects the association of obesity measures with insulin sensitivityJeannie Tay, Amy M Goss, W Timothy Garvey, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 3, 2016
EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HIPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALSPatrick M O'Neil, W Timothy Garvey, J Michael Gonzalez-Campoy, et al.
Kidney International|August 13, 2003
Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathyAlicia J Jenkins, Timothy J Lyons, Deyi Zheng, et al.
Hypertension (Dallas, Tex. : 1979)|December 2, 2025
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1Subodh Verma, Morten Böttcher, Paul Brown, et al.
Atherosclerosis|November 25, 2015
Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetesArpita Basu, Alicia J Jenkins, Ying Zhang, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 11, 2017
Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stressJoo Hyoung Lee, Minsung Kang, Hong Wang, et al.
The Lancet. Diabetes & Endocrinology|September 17, 2025
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trialIldiko Lingvay, Sara J Bergenheim, John B Buse, et al.
JACC. Advances|May 20, 2024
Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in 2 Prospective CohortsCarrie R Howell, Li Zhang, Tapan Mehta, et al.
Pageof 24